1. Home
  2. UAMY vs RIGL Comparison

UAMY vs RIGL Comparison

Compare UAMY & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UAMY
  • RIGL
  • Stock Information
  • Founded
  • UAMY 1968
  • RIGL 1996
  • Country
  • UAMY United States
  • RIGL United States
  • Employees
  • UAMY N/A
  • RIGL N/A
  • Industry
  • UAMY Metal Fabrications
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • UAMY Industrials
  • RIGL Health Care
  • Exchange
  • UAMY Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • UAMY 316.8M
  • RIGL 335.5M
  • IPO Year
  • UAMY N/A
  • RIGL 2000
  • Fundamental
  • Price
  • UAMY $4.25
  • RIGL $39.51
  • Analyst Decision
  • UAMY Strong Buy
  • RIGL Buy
  • Analyst Count
  • UAMY 5
  • RIGL 5
  • Target Price
  • UAMY $3.60
  • RIGL $38.20
  • AVG Volume (30 Days)
  • UAMY 5.1M
  • RIGL 647.0K
  • Earning Date
  • UAMY 08-12-2025
  • RIGL 08-05-2025
  • Dividend Yield
  • UAMY N/A
  • RIGL N/A
  • EPS Growth
  • UAMY N/A
  • RIGL N/A
  • EPS
  • UAMY N/A
  • RIGL 5.43
  • Revenue
  • UAMY $25,728,046.00
  • RIGL $267,921,000.00
  • Revenue This Year
  • UAMY $205.56
  • RIGL $14.41
  • Revenue Next Year
  • UAMY $144.82
  • RIGL $15.97
  • P/E Ratio
  • UAMY N/A
  • RIGL $7.27
  • Revenue Growth
  • UAMY 134.91
  • RIGL 105.62
  • 52 Week Low
  • UAMY $0.40
  • RIGL $11.88
  • 52 Week High
  • UAMY $4.42
  • RIGL $39.72
  • Technical
  • Relative Strength Index (RSI)
  • UAMY 70.10
  • RIGL 93.36
  • Support Level
  • UAMY $3.41
  • RIGL $20.28
  • Resistance Level
  • UAMY $4.04
  • RIGL $21.41
  • Average True Range (ATR)
  • UAMY 0.35
  • RIGL 2.05
  • MACD
  • UAMY 0.07
  • RIGL 1.59
  • Stochastic Oscillator
  • UAMY 89.78
  • RIGL 99.16

About UAMY United States Antimony Corporation

United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company. It has two operating segments: antimony and zeolite. Its products and services include antimony; silver; gold; zeolite products; and storage, handling, & packaging services. The company's geographical segments are the United States, Canada, and Mexico, of which the vast majority of its revenue comes from the United States.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: